Autolus Therapeutics PLC to Discuss the ALLCAR19 Data Presented at AACR Conference Call Transcript
Good day ladies and gentleman and welcome to Autolus Therapeutics Conference Call to discuss the initial results from the company's ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia presented at the AACR annual meeting yesterday.
(Operator Instructions)
As a reminder, this call is being recorded. I would now like to turn the call over to Ms. Silvia Taylor, VP Corporate Affairs and Communications.
Thank you operator and good morning everyone. Thank you for joining our call today to review the initial clinical data from the ongoing Phase 1/2 ALLCAR19 Trial in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia or ALL presented at AACR yesterday as a late-breaking poster.
I am here with Dr. Claire Roddie, principal investigator of the ALLCAR19 trial from University College London in the United Kingdom. Also participating in this call are Dr. Christian Itin, Chairman and CEO; Dr. Martin Pule, Chief Scientific Officer and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |